Document Type : Original Research Article
Authors
1
Department of Traditional Pharmacy, Institute for Studies in Medical History, Persian and Complementary Medicine, School of Persian Medicine, Iran University of Medical Sciences, Tehran, Iran
2
Department of Traditional Medicine, Institute for Studies in Medical History, Persian and Complementary Medicine, School of Persian Medicine, Iran University of Medical Sciences, Tehran, Iran
3
Department of Persian Medicine, Birjand University of Medical Sciences, Birjand, Iran
4
Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran
5
African Medicines Innovations and Technologies Development (AMITD), Indigenous knowledge based Medicines and Innovations Centre, School of Clinical Medicine, Faculty of Health Sciences, University of the Free State, Bloemfontein 9300, South Africa
6
Department of Pharmacology, African Medicines Innovations and Technologies Development (AMITD), Indigenous knowledge based Medicines and Innovations Centre, School of Clinical Medicine, Faculty of Health Sciences, University of the Free State, Bloemfontein 9300, South Africa
10.22038/ajp.2024.24921
Abstract
Objective: Ma’aljobon is used in Persian medicine (PM) as a natural antihypertensive product. This study aimed to evaluate the hypotensive effect of Ma’aljobon in patients with uncontrolled grade 1 primary hypertension (HTN).
Materials and Methods: This double-blind, placebo-controlled clinical trial included 114 patients (20-80 years) with uncontrolled grade 1 primary HTN. After obtaining informed consent, the participants were randomly divided into two groups and administered with 25g of Ma’aljobon or maltodextrin twice daily for six weeks. Systolic and diastolic blood pressures (SBP and DBP, respectively) were analyzed.
Results: A total of 97 patients (52.3±10.7 years, %53.6 female) completed the study. In the Ma’aljobon group, SBP decreased from 150.3±12.3 to 130.6±12.1 mm Hg, and DBP decreased from 93.3±8.2 to 80.1±6.6 mm Hg (p<0.001). In the control group, SBP decreased from 147.6±11.2 to 138.7±14.4 mm Hg, and DBP decreased from 86.6±7.7 to 82.2±8.2 mm Hg (p<0.001). There was a significant difference in the changes of SBP and DBP between the two groups over time (p<0.001). No adverse events were observed.
Conclusion: Ma’aljobon has a stronger hypotensive effect than placebo in patients with HTN and can be recommended as an add-on therapy for uncontrolled HTN.
Keywords
Main Subjects
)